Vol 52, No 2 (2021)
Editorial
Published online: 2021-04-29

open access

Page views 384
Article views/downloads 497
Get Citation

Connect on Social Media

Connect on Social Media

TP53 mutations in chronic lymphocytic leukemia

Tadeusz Robak1
Acta Haematol Pol 2021;52(2):75-76.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Te Raa GD, Kater AP. TP53 dysfunction in CLL: implications for prognosis and treatment. Best Pract Res Clin Haematol. 2016; 29(1): 90–99.
  2. Eichhorst B, Robak T, Montserrat E, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(1): 23–33.
  3. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia. 2009; 23(1): 117–124.
  4. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6): 779–790.
  5. Malcikova J, Pavlova S, Kozubik KS, et al. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. Hum Mutat. 2014; 35(6): 663–671.
  6. Pepek M, Pula B, Machnicki MM, et al. Results of Polish Adult Leukemia Study Group (PALG) project assessing TP53 mutations with next-generation sequencing technology in relapsed and refractory chronic lymphocytic leukemia patients — 18 months update. Acta Haematol Pol. 2021; 52(2): XX–XX.
  7. Rigolin GM, Saccenti E, Bassi C, et al. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol. 2016; 9(1): 88.
  8. Malcikova J, Tausch E, Rossi D, et al. European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia. 2018; 32(5): 1070–1080.
  9. Kantorova B, Malcikova J, Smardova J, et al. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. Tumour Biol. 2015; 36(5): 3371–3380.
  10. Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016; 127(17): 2122–2130.